Tuesday, February 8, 2022
New Haven, CT (Feb 8, 2022) – Yale New Haven Health (YNHHS) has appointed Scott A. Lupkas as vice president, Investments. Lupkas will oversee investment strategy for the YNHH’s nearly $6 billion in investment assets including operating assets, defined pension funds, and endowment as well as special investment programs. He will lead and further develop an in-house investment team focused on asset allocation, manager selection, and risk management efforts that supports the treasurer, the chief financial officer, and the System Investment Committee in the stewardship of assets. Lupkas will report to Michael Angelini, senior vice president, treasurer.
"Scott's diverse investment experience and leadership will enhance our ability to strategically manage Yale New Haven Health’s assets towards achieving mission critical financial objectives," said Angelini.
Lupkas was most recently vice president, Pension Investments for Raytheon Company where he was the chief investment officer overseeing pension and retirement funds including the company's investment strategies and assets for U.S. employee benefit plans. He has more than 20 years of extensive experience advancing investment organizations and managing both traditional and alternative asset class strategies. His previous roles include senior leadership posts at the UAW Retiree Medical Benefits Trust, Verdis Investment Management and the Brown University Investment Office.
“Being a part of Yale New Haven Health, an organization that is committed to innovation and quality in healthcare, research and service to the community, is an honor and I am excited to help ensure its financial strength. It is especially meaningful to me as a native of New Haven County and I am extraordinarily fortunate to be able to give back to an organization that has benefited so many, including my own family,” said Lupkas.
Lupkas holds an MBA from Yale School of Management and a bachelor's degree in economics and international business from New York University. He is a CFA® charterholder.
Yale New Haven Health (YNHHS), one of the largest and most comprehensive healthcare systems in Connecticut, is recognized for advanced clinical care, quality, service, cost effectiveness and commitment to improving the health status of the communities it serves. YNHHS includes five hospitals – Bridgeport, Greenwich, Lawrence + Memorial, Westerly and Yale New Haven hospitals, several specialty networks and Northeast Medical Group, a non-profit medical foundation with several hundred community-based and hospital-employed physicians. YNHHS is affiliated with Yale University and Yale Medicine, the clinical practice of the Yale School of Medicine and the largest academic multi-specialty practice in New England. Yale New Haven Hospital is the primary teaching hospital of Yale School of Medicine. www.ynhhs.org
7/27/2026
Westerly Hospital receives prestigious Emergency Nurses Association Lantern AwardWesterly, RI (July 27, 2026) – Westerly Hospital is proud to announce that its Emergency Department has been honored with the 2026 Emergency Nurses Association (ENA) Lantern Award, a national recognition of excellence in emergency nursing.
7/27/2026
Greenwich Hospital receives State approval to expand cardiac care servicesGREENWICH, CT (July 27, 2026) - Greenwich Hospital announced today that the Connecticut Department of Public Health has approved the hospital’s Certificate of Need (CON) application to establish elective percutaneous coronary intervention (PCI) services, commonly known as coronary angioplasty. The approval allows Greenwich Hospital’s Heart and Vascular Center to provide a broader range of heart procedures locally, reducing the need for patients to be transferred to other hospitals for treatment.
7/21/2026
Yale New Haven Hospital introduces innovative implantable technology to advance stroke rehabilitationNEW HAVEN, CT. — [July 21, 2026] — Every 40 seconds, someone in the United States has a stroke. Yale New Haven Hospital is bringing new hope to stroke survivors with the introduction of an innovative, FDA-approved device that enhances rehabilitation by combining traditional therapy with targeted nerve stimulation.